Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Acta Myol ; 32(2): 100-5, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-24399867

RESUMO

Patients with muscle pathology are a challenge for anaesthesiologists because of possible life-threatening general anaesthesia complications. A review of the current medical literature on the issue clearly indicates that increasing awareness by anaesthesiologists in recent years has led to a reduction in the occurrence of adverse events in patients with diagnostically well-defined muscle disease. On the other hand, the current emerging aspect is that the great majority of complications concern subjects with clinically non-overt (silent to mildly symptomatic) and thus undiagnosed myopathy. With a view to improving prevention of possible critical anaesthesia complications in such patients, we present a "Safe Anaesthesia Table", listing both the anaesthetic drugs to be avoided and those considered harmless for myopathic patients, irrespective of age and type of pathology. In addition, a brief outline about the clinical aspects suggestive of a possible muscle pathology is also provided. Using "safe drugs" during routine surgical procedures in subjects with suspected undiagnosed myopathy will enable the anaesthesiologist to avoid delaying surgery, while protecting them from anaesthesia complications. By following this approach the presumed myopathy can be properly investigated after surgery.


Assuntos
Anestésicos , Erros de Diagnóstico/prevenção & controle , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Doenças Musculares , Adulto , Anestesia/métodos , Anestésicos/administração & dosagem , Anestésicos/efeitos adversos , Anestésicos/classificação , Doenças Assintomáticas , Criança , Contraindicações , Monitoramento de Medicamentos/métodos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/classificação , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/etiologia , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/fisiopatologia , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/prevenção & controle , Humanos , Doenças Musculares/complicações , Doenças Musculares/diagnóstico , Doenças Musculares/fisiopatologia , Dano ao Paciente/prevenção & controle , Cuidados Pré-Operatórios/métodos
2.
In Vivo ; 20(6A): 703-6, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-17203749

RESUMO

Peritoneal carcinomatosis has always been regarded as a contraindication in traditional cancer surgery treatment; however, good results have been reported by using new combined medical-surgical loco-regional techniques. Peritonectomy and chemohyperthermic perfusion with cisplatinum (CIIP) seem to play a central role in obtaining a better survival rate than with the traditional procedures, even though there is a cisplatinum nephrotoxic effect. The aim of this study was to investigate entity and type of renal injury after CIIP. Forty-two patients (12 males and 30 females) with recurrent or primary peritoneal carcinomatosis who underwent peritonectomy and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy with cisplatin were enrolled. A significant worsening in renal function was observed on the third post-operative day and this condition then persisted for three months. A reduction in estimated-Glomerular Filtration Rate (e-GFR) and an alteration in the albumin:creatinine ratio proved tubular injury. On the third post-operative day after cisplatinum administration, a high toxicity peak was found following platinum free fraction excretion. Proximal tubular injury was confirmed even at the three month analysis. A significant correlation between the total protein reduction rate and the decrease in renal function was established. In relation to that, the platinum free fraction could increase because of a binding protein shortage and the nephrotoxic effect could be enhanced due to platinum accumulation within the post-operative period. This finding suggests that the higher the protein reduction is, the lower the e-GFR determination is at three months.


Assuntos
Antineoplásicos/efeitos adversos , Carcinoma/terapia , Cisplatino/efeitos adversos , Nefropatias/induzido quimicamente , Túbulos Renais/efeitos dos fármacos , Neoplasias Peritoneais/tratamento farmacológico , Peritônio/cirurgia , Albuminúria/diagnóstico , Albuminúria/urina , Quimioterapia do Câncer por Perfusão Regional , Terapia Combinada , Creatina/urina , Feminino , Taxa de Filtração Glomerular/efeitos dos fármacos , Humanos , Hipertermia Induzida , Nefropatias/metabolismo , Nefropatias/fisiopatologia , Túbulos Renais/metabolismo , Túbulos Renais/fisiopatologia , Masculino , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa